Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania. Show more

Location: Four Tower Bridge, West Conshohocken, PA, 19428, United States | Website: https://www.madrigalpharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

6.665B

52 Wk Range

$200.63 - $377.46

Previous Close

$300.16

Open

$299.52

Volume

340,923

Day Range

$295.43 - $311.21

Enterprise Value

5.996B

Cash

843.1M

Avg Qtr Burn

-98.83M

Insider Ownership

7.73%

Institutional Own.

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Rezdiffra (Resmetirom) (MGL-3196) Details Non-alcoholic steatohepatitis , Liver disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rezdiffra (Resmetirom) (MGL-3196) Details Liver disease, Cirrhosis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Resmetirom (MGL-3196) Details Fatty liver disease, Liver disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.